clinical-trials

Conditions: STEP 2 · oral semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…

Details up front: SELECT · nausea. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…

The specifics, since they change the answer: PIONEER-1 · 5 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My…

The specifics, since they change the answer: ESSENCE · semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them.…

The particulars: SOUL · 5 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being invited…

Details up front: cagrilintide · 2–8 °C. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence…

The particulars: TRIUMPH-3 · 20 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…

Stated plainly: 5 mg · a GLP-1 receptor agonist. I am trying to build something sustainable rather than something thorough that I will abandon. I have already decided…

Numbers first: cagrilintide · minus 80 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…

Setup, so nobody has to ask: STEP 5 · a GLP-1 receptor agonist. This is asserted often enough that I assumed it was established, and then I went looking for the…

Setup, so nobody has to ask: FLOW · 4 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…

Concretely: SURPASS-3 · injection-site erythema · 20 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading…

Conditions: SURMOUNT-5 · fatigue · 60 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…

The case in front of me: SURMOUNT-4 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…

Stated plainly: SURPASS-3 · cagrilintide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the…

Concretely: ESSENCE · vomiting · 5 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…

The case in front of me: ESSENCE · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if…

The clinician who ordered the panel was not concerned; I would still like to understand it. I keep seeing this stated as a fact with no explanation attached, and…

Stated plainly: TRIUMPH-1 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

Numbers first: cagrilintide · PIONEER-4. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I would…

This matters because it predicts what a related molecule should do. This is one of those things that everyone repeats and nobody derives. This matters practically,…

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I keep seeing this stated as a fact with no explanation attached,…

The specifics, since they change the answer: reflux · ecnoglutide · TRIUMPH-3. I want to understand what this actually establishes, as opposed to what it is being…

For reference: two weeks · survodutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would accept a well-reasoned…